Zeuss: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://getzeuss.com/, in December 2025, and has observed that your website offers compounded drug products, including tirzepatide drug products.

1. 1

   “The compounded tirzepatide products displayed on your website identify “Zeuss” on the pictured label, suggesting Zeuss is the compounder of those drugs when in fact it is not.”

2. 2

   ““each batch rigorously tested for efficacy and safety””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

getzeuss.com returned a live storefront when we checked in August 2026, organised into men's and women's programmes covering body, skin, hair, testosterone and hormone therapy, with a refund promise if a physician does not prescribe. The homepage is largely rendered in the browser and we did not review every page, so we cannot say whether the tirzepatide product named in the letter is still offered.

Read the testing claim carefully, in both directions. "Each batch rigorously tested" is the sentence that answers the question most shoppers actually have about a cheap compounded vial — who checked this? — and FDA's objection is that the sentence sits next to an assertion of FDA approval that the product does not have. What the letter does not do is check any batch or report a defect, so nobody should read it as a finding about what was in the vials. The useful takeaway is about who is making the promise: batch testing by a seller is a claim by the seller, and the compounder that actually made the product was, on FDA's account, someone other than the name on the label. If testing matters to you at the price you are paying, the question worth asking is which facility performed it and what was measured.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Zeuss failed to respond.